Have you ever wondered how cannabinoids interact with your body? The answer is through the endocannabinoid system.

The endocannabinoid system is responsible for regulating balance in our body’s immune response, communication between cells, appetite and metabolism, memory, and more. In spite of the integral role this system takes on, until recently it remained an unknown part of the human body’s functions.

Named for the plant that inspired its discovery, the endocannabinoid system is important to your overall health and equilibrium, but its importance is only just becoming understood by the medical community. It is through this system that the naturally occurring cannabinoids from medical marijuana interact with our bodies and trigger its beneficial effects. With the potential to greatly affect the way our bodies work, a healthy endocannabinoid system is essential and it’s key that we recognize how to maintain it.


Across cultures and building through the 19th century, extractions of the cannabis plant were widely used for a number of medicinal purposes. However, following practical prohibition of the cannabis plant in 1937 by the U.S. government for fear of abuse of its psychoactive properties, the medical use, experimentation, and study of cannabis were eliminated, stalling the progress of our understanding of the endocannabinoid system and the possible medical effects of cannabis. For nearly 50 years, marijuana fell from popular pharmacopeia and was labelled as illicit in the minds of Americans.

Then the endocannabinoid system was defined in the early 1990’s when Lisa Matsuda announced that her team at the National Institute of Mental Health had first identified a THC-sensitive receptor in lab rat brains.

The path to the discovery of the endocannabinoid system, however, started more than a century earlier.

In 1895, researchers T. Barlow Wood, W.T. Newton Spivey, and Thomas Hill Easterfield became the first to isolate and identify a cannabis-derived cannabinoid, cannabinol (CBN) (Wood, Spivey & Easterfield, 1896). Over the next 70 years, researchers identified more cannabinoids, including R. Adams and others who identified and isolated CBD in 1940, and in 1964, Ralph Mechoulam and colleagues isolated and identified tetrahydrocannabinol (THC) (Pertwee, 2006) (Gaoni & Mechoulam, 1964). Following those monumental breakthroughs, researchers spent decades exploring those cannabinoids and their properties.

Before Matsuda’s discovery of the cannabinoid receptor in the animal’s brain, however, it was often speculated that cannabinoids produced their balancing effects via nonspecific interactions. Following this revelation, the National Academy of Science predicted the 1990s would be the “Decade of the Brain”. It turned out to be true as the following 10 year period would produce “more advances in neuroscience than in all previous years combined” (Lee, 2012).

It was in the early and mid-1990s Mechoulam and colleagues officially discovered the endocannabinoid system. It happened after he and his team were able to locate and identify two of the body’s naturally produced major endocannabinoids, anandamide and 2-arachidonoylglycerol, or 2-AG (Mechoulam & Hanus, 2000).

Since then, scientists have labored to learn as much as they can about the endocannabinoid system, our naturally occurring cannabinoids, and the ways cannabis alters this balance, publishing over 20,000 scientific studies referencing cannabinoids in just the last two decades.


The endocannabinoid system is made up of several integrated mechanisms:

  • Enzymes responsible for creating and destroying cannabinoids
  • Receptor sites on cells to receive cannabinoids
  • Endocannabinoids themselves (cannabinoid-like compounds that are naturally produced by the human body)

These mechanisms are predominantly responsible for communication within the body to best regulate various biological responses.

One of the prime questions raised in these early studies was whether or not the body produces its own natural equivalents to the previously discovered compounds called phytocannabinoids, like THC and CBD, found in the cannabis plant (Mandal, 2014). The answer turned out to be “yes” – in the form of the endocannabinoids anandamide and 2-AG, which are like the two prominent analogs to THC and CBD, (Pacher et al, 2006). With the understanding that we humans create our own cannabinoids, the door to deconstructing their purpose was opened.


Endocannabinoids are created in response to needs within the larger physiological system and are largely understood to be used for the body’s regulatory functions. Acting backwards on presynaptic cells, they control the volume at which communicating signals are sent. It is in this way that endocannabinoids affect duration and intensity of the wide range of physiological processes under their control.

However, it has been repeatedly noted that, while the endocannabinoid system is linked to a number of important processes and is concentrated in the brain, nervous system, and reproductive organs, it does not affect regions of the brain controlling heart and lung function. This is one of the main reasons that fatal overdoses of cannabinoids do not occur (NCI, 2016).


Whenever there are deviations from homeostasis in the body’s functions, the endocannabinoid system is activated and begins to respond accordingly by synthesizing endocannabinoids, which act as neurotransmitters.

When the body creates neurotransmitters for the endocannabinoid system, they are picked up by specialized cannabinoid receptors, which sit on the surface of cells. These receptors are found in a wide range of physiological regions, such as in:

  • The immune system
  • Organs and glands
  • Connective tissue
  • The brain (most significantly)

Like a key fits into a lock, endocannabinoids interact with these receptors and transmit information about changing conditions to kick-start a response, with the goal of helping the body achieve homeostasis, or equilibrium, within the body despite outside influences (Alger, 2013).

The endocannabinoid system’s receptor sites include CB1 and CB2 receptor variants, which respond differently to various cannabinoids (Pacher et al, 2006). CB1 receptors are most prevalent in the central nervous system and are linked to the following benefits:

  • Modulation of stress and anxiety
  • Increased appetite
  • Decreased nausea
  • Balance of immune system
  • Inhibition of tumors

CB2 receptors are found mostly on cells in the immune system and seem to dominate in fighting inflammation and damage to tissue. Some cells can even contain both types of receptors, each responsible for a different function.

There are two major endocannabinoids – 2-arachidonoylglycerol (2-AG) and Anandamide (AEA).

2-AG is considered a full agonist of both CB1 and CB2 receptors. This means that it binds with, and fits well inside, both receptors to activate them to stimulate a physiological response.

Anandamide is considered a partial agonist of both receptors, because, while it binds with and activates the receptors, it doesn’t fit as well inside them and subsequently doesn’t trigger such a powerful physiological response (Parcher, Batkai & Kunos, 2006).

Once the function that had deviated from homeostasis returns to equilibrium and the endocannabinoids are no longer needed, the third piece of the system – the metabolic enzymes – breaks down and degrades them.

Fatty acid amide hydrolase (FAAH) degrades Anandamide, and monoacylglycerol lipase (MAGL) breaks down 2-AG. By eliminating the endocannabinoids, the endocannabinoid system “turns off” the molecular signals and ends whatever physiological activity it had stimulated.


Since discovering the endocannabinoid system and its parts, researchers have worked to further understand how the endocannabinoid system may be used therapeutically to:

  • Decrease pain
  • Fight cancer
  • Prevent neurodegenerative diseases
  • Promote general health

Overall, research indicates that the endocannabinoid system helps ensure that the body’s immune and central nervous systems are running correctly. Finding ways to modulate the endocannabinoid system’s activity opens pathways to an amazingly disparate set of chronic diseases and disorders (Pacher and Kunos, 2013).

For example, evidence indicates that stimulation of cannabinoid receptors may aid in the deletion of old traumatic memories and provide clinical benefits in age-related diseases associated with brain inflammation (Ruehle et al, 2012) (Marchalant, et al., 2008). This list also includes difficult conditions like Parkinson’s, multiple sclerosis, and cancer.


There is also evidence that the endocannabinoid system may aid in the deletion of old memories (Ruehle et al, 2012). The extinction of  aversive memories is important to the progress of PTSD patients and in behavior conditioning for those with chronic anxiety.  By allowing patients to forget painful memories, they can reset their stress and anxiety responses to certain experiences and substitute a more positive reaction.

Appetite & Weight

Cannabis has a well-known ability to increase appetite. However, because endocannabinoids are used internally for appetite control, inverse agonists to the CB1 receptor can be used to combat obesity by shutting off the body’s desire for food (Pagotto et al, 2005). The opposite can be accomplished by stimulating appetite in those suffering from wasting syndrome and allowing them to gain weight (Kogan and Mechoulam, 2007).

Finally, endocannabinoids also regulate metabolism and help control the transfer of energy through cells, ensuring optimal use of the food we do take in.


In today’s world, it is a common reality that the natural cycle of anxiety and physical response cannot be shut off due to constant exposure to stressors. Because cannabinoids affect the body’s glandular response to continued stress to regulate and temper response, the endocannabinoid system has implications for the way in which modern humans process long term stress and other enduring anxiety triggers (Akirav).

Immune Function & Inflammation

Additionally, endocannabinoids promote proper immune function to allow for a greater overall wellness. The role they play in immune homeostasis prevents “spontaneous activation of immune cell function”, helping to prevent inflammation and possibly even resulting neurological diseases (Pandey et al, 2009).


As scientists learn more about the endocannabinoid system, they also explore the potential role the cannabis-derived cannabinoids like THC, cannabidiol (CBD), cannabinol (CBN), and more could play in supporting the system.

Cannabinoids mimic the behavior of endocannabinoids and interact with the cannabinoid receptors to augment the endocannabinoid system. As the cannabinoids interact with the cannabinoid receptors, they stimulate various physiological responses.

THC, the well-recognized psychoactive compound found in medical marijuana, activates receptors to elicit a chemical response. It is considered an agonist of both CB1 and CB2 receptors because it directly binds to the receptors and activates them. THC tends to favor CB1 receptors because it fits very well inside them and therefore is able to stimulate a strong physiological reaction.

When THC reacts with CB1 receptors, this is what causes the well-known “high” feeling from marijuana. THC also directly activates CB2 receptors, but is considered a partial agonist and therefore doesn’t elicit such a strong physiological response.

CBD causes chemical changes by blocking receptors. It tends to have low affinity for both CB1 and CB2 receptors, and instead acts as an indirect antagonist of agonists. This means that CBD sits imperfectly inside the receptors, not activating them but preventing other chemical messengers like THC from binding to them (Pacher, Batkai & Kunos, 2006).

As we continue to learn more about the endocannabinoid system, we will also learn about the potential for the scope of active compounds from cannabis (like THC, CBD, and CBN) to be used therapeutically.


One theory about how the endocannabinoid system relates to our overall health is the proposed endocannabinoid deficiency syndrome, or CECD, which speculates that. for some people, the body does not generate enough endocannabinoids (Smith and Wagner, 2014). This concept, originally proposed by researcher E.B. Russo in 2004, further speculates that the deficiency could be the root cause of many autoimmune disorders, including migraines, fibromyalgia, and IBS (Russo, 2004).

By modulating the endocannabinoid system (Kaur, Ambwani & Singh, 2016), several diseases and conditions could possibly be treated, including:

  • Pain
  • Inflammation
  • Multiple sclerosis
  • Anorexia
  • Epilepsy
  • Cancer
  • Glaucoma
  • Obesity
  • Schizophrenia
  • Cardiovascular disorders
  • Parkinson’s disease
  • Huntington’s disease
  • Alzheimer’s disease
  • Tourette’s syndrome

One of the main obstacles to the acceptance and use of cannabis and its active cannabinoids in medicine is the problem of abuse for its psychoactivity. However, this issue does not arise in a number of possible approaches to the regulation of the endocannabinoid system:

  • When an antagonist to the CB1 receptor is applied
  • When the production or transportation of endocannabinoids is altered
  • When a non-psychoactive agonist to the CB2 receptor, like CBD, is used for therapeutic results (Pacher and Kunos, 2013).

Phytocannabinoids, like the THC from cannabis or the concentrated CBD in hemp, obviously affect the endocannabinoid system. However, it has also been shown that non-psychoactive phytocannabinoids from other plants, and even other compounds like terpenes and flavonoids, are picked up by receptors in our endocannabinoid systems (Gertsch et al, 2010).

Because small doses of phytocannabinoids can encourage the body to create more naturally occurring endocannabinoids and their receptors, it may be possible to bolster the sensitivity of our native systems with regular cannabinoid supplements (Pacher et al, 2006).

Overall, significant research must still be done to better understand the impact of the endocannabinoid system on our overall health and how supplementing our natural endocannabinoid production with plant-based cannabinoids may play a significant therapeutic role in our health. However, extensive early studies show great potential for using this vital system to the benefit of patient health.


Akirav, I. (n.d.) Role of the endocannabinoid system in anxiety and stress-related disorders. Intech Open. Retrieved from http://cdn.intechopen.com/pdfs/17314/InTech-Role_of_the_endocannabinoid_system_in_anxiety_and_stress_related_disorders.pdf

Alger, B. E. (2013). Getting High on the Endocannabinoid System. Cerebrum: The Dana Forum on Brain Science, 2013, 14. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3997295

Gaoni, Y., and Mechoulam, R. (1964). Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish. Journal of the American Chemical Society, 86(8), 1646-47. Retrieved from http://pubs.acs.org/doi/abs/10.1021/ja01062a046.

Gertsch, J., Pertwee, R. G., & Di Marzo, V. (2010). Phytocannabinoids beyond the Cannabis plant – do they exist? British Journal of Pharmacology, 160(3), 523–529. Retrieved from http://doi.org/10.1111/j.1476-5381.2010.00745.x

Kaur, R., Ambwani, S.R., Singh, S. (2016). Endocannabinoid system: A multi-facet therapeutic target. Current Clinical Pharmacology, 11(2), 110-7. Retrieved from http://www.eurekaselect.com/141330/article.

Kogan, N. M., & Mechoulam, R. (2007). Cannabinoids in health and disease. Dialogues in Clinical Neuroscience, 9(4), 413–430. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202504.

Lee, M. (2012). The Discovery of the endocannabinoid system. Retrieved fromhttp://www.beyondthc.com/wp-content/uploads/2012/07/eCBSystemLee.pdf

Mandal, A. (2014, June 14). Phytocannabinoids. News Medical. Retrieved from http://www.news-medical.net/health/Phytocannabinoids.aspx.

Marchalant, Y., Cerbai, F., Brothers, H.M., & Wenk, G.L. (2008). Cannabinoid receptor stimulation is anti-inflammatory and improves memory in old rats. Neurobiology of Aging, 29(12), 1894–1901. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2586121.

Mechoulam, R., and Hanus, L (2000, November). A historical overview of chemical research on cannabinoids. Chemistry and Physics of Lipids, 108(1-2), 1-13. Retrieved fromhttp://www.sciencedirect.com/science/article/pii/S0009308400001845.

National Cancer Institute. (2016). Cannabis and cannabinoids. Retrieved fromhttp://www.cancer.gov/about-cancer/treatment/cam/hp/cannabis-pdq#section/_11

Pacher, P., Batkai, S., & Kunos, G. (2006). The Endocannabinoid System as an Emerging Target of Pharmacotherapy. Pharmacological Reviews, 58(3), 389–462. http://doi.org/10.1124/pr.58.3.2. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2241751.

Pacher, P., & Kunos, G. (2013). Modulating the endocannabinoid system in human health and disease: successes and failures. The FEBS Journal, 280(9), 1918–1943. Retrieved from http://doi.org/10.1111/febs.12260.

Pagotto, U., Vicennati, V., & Pasquali, R. (2005). The endocannabinoid system and the treatment of obesity. Annals of Medicine. 37(4):270-5. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/16019725.

Pandey, R., Mousawy, K., Nagarkatti, M., & Nagarkatti, P. (2009). Endocannabinoids and immune regulation. Pharmacological Research : The  Official Journal of the Italian Pharmacological Society, 60(2), 85–92. Retrieved from http://doi.org/10.1016/j.phrs.2009.03.019.

Pertwee, R.G. (2006). Cannabinoid pharmacology: the first 66 years. British Journal of Pharmacology, 147(Suppl 1), S163-S171. Retrieved fromhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1760722.

Ruehle, S., Rey, A. A., Remmers, F., & Lutz, B. (2012). The endocannabinoid system in anxiety, fear memory and habituation. Journal of Psychopharmacology (Oxford, England), 26(1), 23–39. Retrieved from http://doi.org/10.1177/0269881111408958.

Smith, S. & Wagner, M. (2014) Clinical endocannabinoid deficiency (CECD) revisited: can this concept explain the therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions. Neuro Endocrinol Letters. 35(3):198-201. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/24977967.

Wood, T.B., Spivey, W.T.N., and Easterfield, T.H. (1896). XL. – Charas. The resin of Indian hemp. Journal of the Chemical Society, Transactions, 69, 539-546. Retrieved fromhttp://pubs.rsc.org/en/content/articlelanding/1896/ct/ct8966900539#!divAbstract.